Concarlo Therapeutics
12:00 PM - 12:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics to target drug-resistant cancers.
Concarlo is developing therapies to drug the master regulator, p27, the direct inhibitor of the three highest value targets in oncology, CDK4/CDK6 and CDK2. An effective triple CDK2/4/6 would clean up the drug resistance seen in the presence of most RAS/MAPK pathway inhibitors and has broad application across numerous tumor types. We aim to enter the market as an alternative to chemotherapy for patients who have failed off prior lines of CDK4i therapies (the lucrative post CDK4i-space) or other precision oncology inhibitors, such as those used in breast, ovarian, or advanced melanoma cancers.
Concarlo is developing therapies to drug the master regulator, p27, the direct inhibitor of the three highest value targets in oncology, CDK4/CDK6 and CDK2. An effective triple CDK2/4/6 would clean up the drug resistance seen in the presence of most RAS/MAPK pathway inhibitors and has broad application across numerous tumor types. We aim to enter the market as an alternative to chemotherapy for patients who have failed off prior lines of CDK4i therapies (the lucrative post CDK4i-space) or other precision oncology inhibitors, such as those used in breast, ovarian, or advanced melanoma cancers.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Our lead p27 inhibitor, IpY, is peptide:liposomal drug, based on the endogenous p27 agonist. We are following nature's lead to effectively and safely inhibit CDK2/4/6. Concarlo is finishing CMC and expects to obtain IND approval for our Ph1 trial in 18 months.
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
